Ascent Group’s AnaptysBio ANAB Stock Holding History

Ascent Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$378K	Sell	5,598 -24	-0.4%	-$1.46K	0.01%	606
2026 Q1	$312K	Sell	5,622 -40	-0.7%	-$2.15K	0.01%	614
2025 Q4	$274K	Buy	+5,662	New	+$221K	0.01%	638

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Ascent Group's ANAB Position: Q2 2026 in Review

Ascent Group reduced its AnaptysBio (ANAB) stake by 0.43% in Q2 2026, selling an estimated $1.46K and leaving 5,598 shares worth $378K. The position accounts for 0.01% of the portfolio, ranked #606.

Ascent Group first reported a position in ANAB in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Ascent Group held 5,598 shares of AnaptysBio worth $378K as of Q2 2026.
Ascent Group sold 24 AnaptysBio shares in Q2 2026, an estimated $1.46K.
AnaptysBio made up 0.01% of Ascent Group's portfolio in Q2 2026, its #606 holding.
Ascent Group first reported a position in AnaptysBio in Q4 2025 and has held it in 3 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Ascent Group's 13F filing for Q2 2026, filed 3 Aug 2026.